Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$44.2 million.

  • Entrada Therapeutics' Consolidated Net Income fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • Per Entrada Therapeutics' latest filing, its Consolidated Net Income stood at -$44.2 million for Q3 2025, which was down 2.45% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' Consolidated Net Income's 5-year high stood at $55.0 million during Q2 2024, with a 5-year trough of -$44.2 million in Q3 2025.
  • For the 3-year period, Entrada Therapeutics' Consolidated Net Income averaged around -$4.2 million, with its median value being -$9.5 million (2023).
  • In the last 5 years, Entrada Therapeutics' Consolidated Net Income surged by 449.49% in 2024 and then slumped by 215.75% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Consolidated Net Income stood at -$24.6 million in 2022, then surged by 61.43% to -$9.5 million in 2023, then skyrocketed by 111.63% to $1.1 million in 2024, then crashed by 215.75% to -$44.2 million in 2025.
  • Its last three reported values are -$44.2 million in Q3 2025, -$43.1 million for Q2 2025, and -$17.3 million during Q1 2025.